Conference bringing together biotech, life sciences and businesses

Posted by on May 4, 2016 in Newsroom | 0 comments

BIRMINGHAM, AL. – The important and potentially lucrative convergence of biotechnology, life sciences and business will be the subject of an important meeting in Birmingham next week. BioAlabama, the state’s biotechnology and life science trade association, will host a conference at the Birmingham Westin on May 11 where leaders in biotechnology, life sciences and business will meet to talk about opportunities to transition scientific research to industry. The theme of the conference is “Building Alabama Biotech: Emerging Business, Talent and Innovation,” The goal of...

Read More

Novartis-backed Viamet Pharmaceuticals sets terms for $86 million IPO

Posted by on May 4, 2016 in Newsroom | 0 comments

DURHAM, N.C. – Viamet Pharmaceuticals Holdings, a biotech developing metal-binding protein therapeutics to treat fungal diseases, announced terms for its IPO on Tuesday. The Durham, NC-based company plans to raise $86 million by offering 5.7 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range, Viamet Pharmaceuticals Holdings would command a fully diluted market value of $389 million. Viamet Pharmaceuticals Holdings was founded in 2004. It plans to list on the Nasdaq under the...

Read More

Jupiter, FL. could lend money to relocating biotech company

Posted by on Apr 29, 2016 in Newsroom | 0 comments

JUPITER, FL. – Jupiter could provide a $350,000 loan guarantee to a relocating biotech company, which would be on top of a previous award. The town council will vote May 3 on granting “Project Pick,” the code name for CTD Holdings, the loan from its economic development fund. The fund was set up to support the growth of biotech companies after the Scripps Research Institute opened a campus in Jupiter. On April 19, the town council approved CTD Holdings for a $357,000 job growth incentive award, with $71,400 from the city and the rest from the state. The company would earn the money...

Read More

Aurobindo Pharma USA, Inc. To Establish National Headquarters In Durham, North Carolina

Posted by on Apr 27, 2016 in Newsroom | 0 comments

DURHAM, N.C. – India-based Aurobindo Pharma USA, Inc. will bring 275 new R&D and pharma-manufacturing jobs to Durham, North Carolina. The New Jersey-based maker of generic pharmaceuticals plans to invest over $31.7 million in a new state-of-the-art national headquarters for specialty pharmaceutical R&D. Aurobindo Pharma USA will establish a new R&D and manufacturing center in Durham. The company currently employs 14 scientists/workers in Raleigh. Among the new employees will be researchers, analytical chemists, production operators, quality control specialists and...

Read More

NC Biotechnology Center awards $2.5M in latest round of grants, loans

Posted by on Apr 27, 2016 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – The North Carolina Biotechnology Center awarded 21 grants and loans totaling $2.5 million to companies, universities and nonprofit organizations across the state during the third quarter of its 2015-2016 fiscal year ending March 31. The funding will support research infrastructure, product development and commercialization, and business and technology events – all vital to growing the state’s bioscience industry and creating high-paying jobs. Four bioscience companies received loans totaling $1.25 million to support product research and...

Read More

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institut

Posted by on Apr 21, 2016 in Newsroom | 0 comments

JACKSONVILLE, FL. – TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRα), in combination with Astra Zeneca (NYSE: AZN) durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study will commence in the second quarter of 2016 at Memorial...

Read More